All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation
During the 2021 ASCO Annual Meeting, the Multiple Myeloma Hub spoke with Parameswaran Hari, Medical College of Wisconsin, Milwaukee, US. We asked, What are the challenges and possibilities of circulating tumor DNA (ctDNA) to monitor response and relapse in MM?
What are the challenges and possibilities of ctDNA to monitor response and relapse in MM?
Using ctDNA to detect minimal residual disease (MRD) in the peripheral blood presents a sensitive, noninvasive technique to predict relapse in patients with multiple myeloma (MM). Hari outlines the advantages of ctDNA analysis over bone marrow aspiration, and presents data from a study investigating the prognostic value of ctDNA in patients with MM following auto-HCT.
Educational theme: Measurable residual disease (MRD)
This month’s educational theme on the Multiple Myeloma (MM) Hub is centered around measurable residual disease (MRD; also referred to as minimal residual disease).
What you need to know about keratopathy management with belamaf
During the 2021 ASCO Annual Meeting, the Multiple Myeloma Hub spoke with Evangelos Terpos, National and Kapodistrian University of Athens, Athens, GR. He discusses what you need to know...
Subscribe to get the best content related to multiple myeloma delivered to your inbox